Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Tuesdays: X-article on biotech hot topics
Wednesdays: Podcast format of X-article
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Saturdays: Podcast format of Weekly News Update
Sundays: Building Biotech: Strategic Topics
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the Bowtied Biotech Podcast, where we dive into the pulse of the biotech industry, unpacking the stories shaping science, medicine, and markets. In today’s episode, we dissect the fallout from Neumora Therapeutics’ Phase 3 trial failure for its depression drug, navacaprant, which sent the company’s stock plummeting over 80%. We’ll explore the ripple effects of this "worst-case scenario" outcome, what it means for major depressive disorder treatments, and the trends reshaping drug development. Plus, we’ll connect the dots to the broader industry landscape, from Pfizer’s retreat in gene therapy to Roche’s $1 billion ADC deal in China. Stick around for insights you won’t want to miss!
📣🎙️ TODAY’S POCAST:
( 0:00 ) Intro and Welcome
( 1:00 ) Neumora Phase 3 Failure
( 2:45 ) Pfizer Exits Gene Therapy
( 4:19 ) Rise of ADCs
( 6:00 ) Roche’s $1B ADC Deal
( 6:42 ) China’s Role in Biotech
( 7:37 ) Personalized Medicine Trends
( 8:14 ) Advances in Genetic Testing
( 9:00 ) AI in Health Care
( 9:47 ) Challenges in Personalized Medicine
( 11:14 ) Ethical Considerations in Biotech
( 12:03 ) AI Revolution in Biotech
( 16:45 ) Closing and Thanks
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post